Syros Pharmaceuticals, Inc. financial data

Symbol
SYRS on Nasdaq
Industry
Pharmaceutical Preparations
Location
35 Cambridge Park Drive, Cambridge, MA
State of incorporation
DE
Fiscal year end
December 31
Former names
LS22, Inc. (to 8/22/2012)
Latest financial report
10-Q - Q3 2024 - Oct 31, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 320 % -46.2%
Return On Equity -2.75K % -2151%
Return On Assets -79.1 % -46.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 26.8M shares
Common Stock, Shares, Outstanding 26.8M shares +29.5%
Entity Public Float 58.6M USD +5.06%
Common Stock, Value, Issued 27K USD +28.6%
Weighted Average Number of Shares Outstanding, Basic 39.3M shares +40.5%
Weighted Average Number of Shares Outstanding, Diluted 39.3M shares +40.5%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 9.94M USD -33.2%
Research and Development Expense 88.6M USD -22.6%
General and Administrative Expense 23.3M USD -21.7%
Operating Income (Loss) -112M USD +19%
Net Income (Loss) Attributable to Parent -97.8M USD +6.81%
Earnings Per Share, Basic -3.08 USD/shares -301%
Earnings Per Share, Diluted -3.08 USD/shares -301%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.3M USD -48.1%
Marketable Securities, Current 24.8M USD -59.4%
Cash, Cash Equivalents, and Short-term Investments 108M USD
Assets, Current 63.9M USD -47.8%
Property, Plant and Equipment, Net 6.31M USD -17.2%
Operating Lease, Right-of-Use Asset 11.3M USD -9.57%
Other Assets, Noncurrent 1.37M USD -35.4%
Assets 85M USD -42.5%
Accounts Payable, Current 9.65M USD +238%
Employee-related Liabilities, Current 4.79M USD -39.7%
Liabilities, Current 28.4M USD -0.01%
Operating Lease, Liability, Noncurrent 16.6M USD -13.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 49K USD
Retained Earnings (Accumulated Deficit) -756M USD -14.9%
Stockholders' Equity Attributable to Parent -11.1M USD -131%
Liabilities and Equity 85M USD -42.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -31.1M USD +15.7%
Net Cash Provided by (Used in) Financing Activities -265K USD
Net Cash Provided by (Used in) Investing Activities -24.6M USD +4.3%
Common Stock, Shares Authorized 140M shares +100%
Common Stock, Shares, Issued 26.8M shares +29.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -56M USD +10.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.4M USD -47.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 1.21M USD +14.8%
Deferred Tax Assets, Valuation Allowance 169M USD +31.7%
Deferred Tax Assets, Gross 174M USD +29.8%
Operating Lease, Liability 20.3M USD -9.3%
Payments to Acquire Property, Plant, and Equipment 235K USD +83.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -97.8M USD +6.61%
Lessee, Operating Lease, Liability, to be Paid 26.7M USD -13.3%
Property, Plant and Equipment, Gross 14.9M USD -37.5%
Operating Lease, Liability, Current 2.58M USD +15.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.41M USD +2.92%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.29M USD +2.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.38M USD -23.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 4.54M USD +2.92%
Deferred Tax Assets, Operating Loss Carryforwards 95.3M USD +16.2%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.54M USD +2.92%
Operating Lease, Payments 1.04M USD +2.98%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 334K USD -47.6%
Deferred Tax Assets, Net of Valuation Allowance 4.72M USD -14.2%
Share-based Payment Arrangement, Expense 7.25M USD -37.6%
Interest Expense 5.32M USD +13.9%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%